tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

INSM Stock Latest News

Insmed price target raised to $193 from $154 at TD Cowen
The FlyInsmed price target raised to $193 from $154 at TD Cowen
6d ago
INSM
Insmed’s TPIP Shows Promising Phase 2 Results, Boosting Buy Rating and Future Prospects
PremiumRatings
Insmed’s TPIP Shows Promising Phase 2 Results, Boosting Buy Rating and Future Prospects
6d ago
INSM
Insmed price target raised to $180 from $110 at Evercore ISI
PremiumThe Fly
Insmed price target raised to $180 from $110 at Evercore ISI
7d ago
INSM
Measured Optimism and Caution: Maxwell Skor’s Hold Rating on Insmed Amid Promising Brinsupri Launch
PremiumRatings
Measured Optimism and Caution: Maxwell Skor’s Hold Rating on Insmed Amid Promising Brinsupri Launch
8d ago
INSM
Insmed to present multiple abstracts from ERS Congress 2025
PremiumThe Fly
Insmed to present multiple abstracts from ERS Congress 2025
16d ago
INSM
Promising Market Potential for Insmed’s Brensocatib Drives Buy Rating
PremiumRatingsPromising Market Potential for Insmed’s Brensocatib Drives Buy Rating
27d ago
INSM
Insmed price target raised to $172 from $125 at Guggenheim
Premium
The Fly
Insmed price target raised to $172 from $125 at Guggenheim
30d ago
INSM
Insmed’s Strategic Advancements and Market Potential: A Buy Recommendation
Premium
Ratings
Insmed’s Strategic Advancements and Market Potential: A Buy Recommendation
1M ago
INSM
Optimistic Buy Rating for Insmed: TPIP’s Potential in the IPF Market
PremiumRatings
Optimistic Buy Rating for Insmed: TPIP’s Potential in the IPF Market
1M ago
INSM
Cautious Hold Rating on Insmed Amid Positive IPF Trial Results and Awaited Strategic Clarity
PremiumRatings
Cautious Hold Rating on Insmed Amid Positive IPF Trial Results and Awaited Strategic Clarity
1M ago
INSM
Insmed’s Growth Potential Highlighted by TPIP’s Market Opportunity and Positive Outlook
PremiumRatings
Insmed’s Growth Potential Highlighted by TPIP’s Market Opportunity and Positive Outlook
1M ago
INSM
Buy Rating for Insmed: Promising Market Potential and Strategic Advancements in TPIP Development
PremiumRatings
Buy Rating for Insmed: Promising Market Potential and Strategic Advancements in TPIP Development
1M ago
INSM
Insmed strength on United Therapeutics read through ‘warranted,’ says BofA
PremiumThe FlyInsmed strength on United Therapeutics read through ‘warranted,’ says BofA
1M ago
INSM
UTHR
Optimistic Buy Rating for Insmed’s TPIP Driven by Promising TETON-2 Trial Results and Market Potential in IPF Treatment
Premium
Ratings
Optimistic Buy Rating for Insmed’s TPIP Driven by Promising TETON-2 Trial Results and Market Potential in IPF Treatment
1M ago
INSM
Insmed has positive read from United Therapeutics data, says Stifel
Premium
The Fly
Insmed has positive read from United Therapeutics data, says Stifel
1M ago
INSM
UTHR
Insmed removed from US Conviction List at Goldman Sachs
PremiumThe Fly
Insmed removed from US Conviction List at Goldman Sachs
1M ago
INSM
Insmed treatment of Duchenne muscular dystrophy granted orphan designation
PremiumThe Fly
Insmed treatment of Duchenne muscular dystrophy granted orphan designation
1M ago
INSM
Insmed price target raised to $144 from $126 at Morgan Stanley
PremiumThe Fly
Insmed price target raised to $144 from $126 at Morgan Stanley
2M ago
INSM
Insmed’s Promising Future: Buy Rating Backed by Brinsupri Approval and Strategic Growth Prospects
PremiumRatings
Insmed’s Promising Future: Buy Rating Backed by Brinsupri Approval and Strategic Growth Prospects
2M ago
INSM
Insmed price target raised to $135 from $111 at JPMorgan
PremiumThe FlyInsmed price target raised to $135 from $111 at JPMorgan
2M ago
INSM
Insmed initiated with an Outperform at William Blair
Premium
The Fly
Insmed initiated with an Outperform at William Blair
2M ago
INSM
Insmed’s Growth Potential: Buy Rating Backed by Strong Clinical Execution and Market Expansion Opportunities
Premium
Ratings
Insmed’s Growth Potential: Buy Rating Backed by Strong Clinical Execution and Market Expansion Opportunities
2M ago
INSM

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >